Print this page
-
A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors.
Protocol: 072310Principal Investigator:
- Matthew Deek (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Rectum
Prostate
Small Intestine -
Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere ) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy
Protocol: 072311Principal Investigator:
- Sharon Li (Rutgers University)
Applicable Disease Sites: Liver -
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab.
Protocol: 072213Principal Investigator:
- Sharon Li (Rutgers University)
Applicable Disease Sites: Liver -
A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination with Hydroxychloroquine in Patients with Advanced Gastrointestinal Malignancies Harboring MAPK Pathway Mutations.
Protocol: 052216Principal Investigator:
- Sanjay Goel (Rutgers University)
Applicable Disease Sites: Anus
Small Intestine
Colon
Esophagus
Stomach
Rectum
Other Digestive Organ
Pancreas -
A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen.
Protocol: 072214Principal Investigator:
- Howard Hochster M.D (Rutgers University)
Applicable Disease Sites: Other Digestive Organ -
A Phase 2 Study of CTX-009 in Adult Patients with Metastatic Colorectal Cancer who have received Two or Three Prior Systemic Chemotherapy Regimens.
Protocol: 072301Principal Investigator:
- Patrick Boland (Rutgers University)
Applicable Disease Sites: Colon